DBV Technologies (NASDAQ:DBVT) Share Price Crosses Above 50-Day Moving Average - Should You Sell?

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $8.63 and traded as high as $8.76. DBV Technologies shares last traded at $8.55, with a volume of 32,186 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. HC Wainwright raised their price target on DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research note on Monday, May 5th. Wall Street Zen raised shares of DBV Technologies from a "sell" rating to a "hold" rating in a research report on Friday, May 9th. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research report on Tuesday, May 27th. JMP Securities lifted their price objective on shares of DBV Technologies from $15.00 to $21.00 and gave the company a "market outperform" rating in a report on Tuesday, May 27th. Finally, The Goldman Sachs Group raised DBV Technologies to a "sell" rating and set a $7.25 target price on the stock in a research report on Thursday, May 29th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $14.75.

DBV Technologies Stock Performance

The business's fifty day moving average price is $8.72 and its two-hundred day moving average price is $5.72. The firm has a market capitalization of $237.75 million, a P/E ratio of -1.93 and a beta of -0.63.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. The firm had revenue of $0.51 million during the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. Sell-side analysts predict that DBV Technologies S.A. will post -7.05 earnings per share for the current year.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors and hedge funds own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.